Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Cortes JE, Roboz GJ, Baer MR, Jonas BA, Schiller GJ, Yee K, Ferrell PB, Yang J, Wang ES, Blum WG, Mims A, Tian H, Sheppard A, de Botton S, Montesinos P, Curti A, Watts JM; Olutasidenib Combination Therapy Study Group. Cortes JE, et al. Among authors: wang es. J Hematol Oncol. 2025 Jan 16;18(1):7. doi: 10.1186/s13045-024-01657-z. J Hematol Oncol. 2025. PMID: 39819505 Clinical Trial.
Breeding and biotechnology approaches to enhance the nutritional quality of rapeseed byproducts for sustainable alternative protein sources- a critical review.
Manikandan A, Muthusamy S, Wang ES, Ivarson E, Manickam S, Sivakami R, Narayanan MB, Zhu LH, Rajasekaran R, Kanagarajan S. Manikandan A, et al. Among authors: wang es. Front Plant Sci. 2024 Nov 11;15:1468675. doi: 10.3389/fpls.2024.1468675. eCollection 2024. Front Plant Sci. 2024. PMID: 39588088 Free PMC article. Review.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Luskin MR, Murakami MA, Keating JH, Flamand Y, Winer ES, Garcia JS, Stahl M, Stone RM, Wadleigh M, Jaeckle SL, Hagopian E, Weinstock DM, Liegel J, McMasters M, Wang ES, Stock W, DeAngelo DJ. Luskin MR, et al. Among authors: wang es. Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800. Online ahead of print. Blood. 2024. PMID: 39374521
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Adès L, Heiblig M, Berthon C, Peterlin P, Rodríguez-Arbolí E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT. Wang ES, et al. Lancet Oncol. 2024 Oct;25(10):1310-1324. doi: 10.1016/S1470-2045(24)00386-3. Lancet Oncol. 2024. PMID: 39362248 Clinical Trial.
How I Treat: Secondary Acute Myeloid Leukemia.
Green SD, Wang ES. Green SD, et al. Among authors: wang es. Blood. 2024 Oct 2:blood.2024024011. doi: 10.1182/blood.2024024011. Online ahead of print. Blood. 2024. PMID: 39356870
PTPN11 Mutation Clonal Hierarchy in Acute Myeloid Leukemia.
Fobare S, Sharpe C, Quinn K, Bryant K, Miles LA, Bowman RL, Cheney C, Furby C, Long M, Fyock K, Wronowski B, Lerma JR, Mullaney A, Mrózek K, Nicolet D, Sesterhenn T, Johnstone ME, Rai SN, Pasare C, Zimmermann N, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Perentesis JP, Eisfeld AK, Hertlein E, Byrd JC. Fobare S, et al. Among authors: wang es. bioRxiv [Preprint]. 2024 Sep 20:2024.09.18.612239. doi: 10.1101/2024.09.18.612239. bioRxiv. 2024. PMID: 39345464 Free PMC article. Preprint.
284 results